asbestos lawyers - Worthington & Caron, PC

Over $2.5 billion

obtained for mesothelioma patients & families

In The News

Tazemetostat Proves Effective in Treatment of Mesothelioma with BAP1 Mutation

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have published promising results of a phase 2 clinical trial for patients with pleural mesothelioma found to have a BAP1 genetic mutation.

According to the researchers, the BAP1 mutation is found in over 50% of patients with pleural mesothelioma.

Researchers administered Tazemetostat (Tazverik®) orally to 74 patients whose mesothelioma was found to contain the BAP1 mutation and had previously undergone chemotherapy. The drug was administered in 21-day cycles for approximately 17 cycles. After a median follow-up of 35·9 weeks the disease control rate in part 2 was 54% at week 12.

The phase 2 trial was led by MSK oncologist Marjorie Zauderer, “This is the first targeted therapy we’ve seen to have a real effect on slowing or stopping pleural mesothelioma,” Dr. Zauderer says. “After we found out how common BAP1 was in mesothelioma, I took action to make sure every mesothelioma case at MSK was tested for the mutation.”

The study was published May 16, 2022 in the journal Lancet Oncology.

Get Empowered

We put your medical and personal needs first and provide compassionate representation.

Please enter the captcha above: